Content area

|
|

Flibanserin som farmakologisk behandling af nedsat lyst hos kvinder

Forfattere
Anne Sofie Eldon1 & Annamaria Giraldi2, 3 1) Sundhedsvidenskabeligt Fakultet, Københavns Universitet 2) Sexologisk Klinik, Psykiatrisk Center København 3) Institut for Klinisk Medicin, Københavns Universitet Ugeskr Læger 2017;179:V03160209
Reference: 
Ugeskr Læger 2017;179:V03160209
Blad nummer: 
Sidetal: 
2-6
Flibanserin as pharmacological therapy of inhibited sexual desire in women
Flibanserin was approved by the Food and Drug Administration in the USA in August 2015 as the first drug for the treatment of American women with the dysfunction hypoactive sexual desire disorder (HSDD) and is a 5-HT1A agonist and 5-HT2A antagonist. The neurophysiological effects of flibanserin on these receptors are consistent with the clinical effects, i.e. significantly increasing sexual desire and frequency of satisfying sexual experiences. As such, shifting the balance between inhibitory and excitatory neurotransmitters of importance to sexual desire, flibanserin pharmacologically broaches a possible new approach to the treatment of HSDD.

💬 0 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Anders Beich | 24/04
1 Kommentar
af Brian Jørn Lerche | 24/04
4 kommentarer
af Søren Gunnar Friborg | 23/04
1 Kommentar
af Lars Borly | 22/04
1 Kommentar
af Hanne Hulgaard | 22/04
1 Kommentar
af Per Kristian Kruhøffer | 21/04
1 Kommentar
af Kristian Rørbæk Madsen | 21/04
6 kommentarer
af Alice Kunkel | 21/04
1 Kommentar
af Klaus Larsen | 18/04
2 kommentarer
af Elo Aagaard Rasmussen | 17/04
5 kommentarer